DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Thalomid (Thalidomide) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

The most serious toxicity associated with thalidomide is its documented human teratogenicity. (See  BOXED WARNINGS and CONTRAINDICATIONS.) The risk of severe birth defects, primarily phocomelia or death to the fetus, is extremely high during the critical period of pregnancy. The critical period is estimated, depending on the source of information, to range from 35 to 50 days after the last menstrual period. The risk of other potentially severe birth defects outside this critical period is unknown, but may be significant. Based on present knowledge, thalidomide must not be used at any time during pregnancy.

Because thalidomide is present in the semen of patients receiving the drug, males receiving thalidomide must always use a latex condom during any sexual contact with women of childbearing potential.

Thalidomide is associated with drowsiness/somnolence, peripheral neuropathy, dizziness/orthostatic hypotension, neutropenia, and HIV viral load increase. (See WARNINGS)

Hypersensitivity to THALOMID® (thalidomide) and bradycardia in patients treated with thalidomide have been reported. (See PRECAUTIONS)

Somnolence, dizziness, and rash are the most commonly observed adverse events associated with the use of thalidomide. Thalidomide has been studied in controlled and uncontrolled clinical trials in patients with multiple myeloma and ENL and in people who are HIV-seropositive. In addition, thalidomide has been administered investigationally for more than 20 years in numerous indications. Adverse event profiles from these uses are summarized in the sections that follow.

Other Adverse Events

Due to the nature of the longitudinal data that form the basis of this product’s safety evaluation, no determination has been made of the causal relationship between the reported adverse events listed below and thalidomide. These lists are of various adverse events noted by investigators in patients to whom they had administered thalidomide under various conditions. The use of thalidomide may not limit disease progression and/or death.

Adverse Events in Multiple Myeloma Controlled Clinical Trial

The safety analysis was conducted on 204 patients who received study drug in the randomized trial. Table 6 lists the most common treatment–emergent signs and symptoms (occurring at ≥ 10%) that were observed. The most frequently reported adverse events were constipation, sensory neuropathy, confusion, hypocalcemia, edema, dyspnea, thrombosis/embolism, and rash/desquamation (occurring in ≥20% of patients and with a frequency of ≥ 10% in patients treated with THALOMID® (thalidomide)/dexamethasone compared with dexamethasone alone).

Twenty-three percent of patients (47/204) discontinued due to adverse events; thirty percent (31/102) from the THALOMID® (thalidomide)/dexamethasone arm and sixteen percent (16/102) from the dexamethasone alone arm.

 Table 6:  Treatment-Emergent Adverse Events in ≥ 10% of All Patients  Adverse Event (Safety Population; N=204)

Organ System
Class/Preferred
Term

Thal + Dex (N=102)

Dex Alone (N=102)

All
Events

[n,(%)]

Grade 3
Events

[n,(%)]

Grade 4
Events

[n,(%)]

All
Events

[n,(%)]

Grade 3
Events

[n,(%)]

Grade 4
Events

[n,(%)]

Metabolic/Laboratory

97 (95.1)

30 (29.4)

15 (14.7)

96 (94.1)

28 (27.5)

6 (5.9)

Hyperglycemia

74 (72.5)

12 (11.8)

4 (3.9)

81 (79.4)

17 (16.7)

2 (2.0)

Hypocalcemia

73 (71.6)

9 (8.8)

6 (5.9)

60 (58.8)

4 (3.9)

1 (1.0)

Hyponatremia

44 (43.1)

11 (10.8)

2 (2.0)

49 (48.0)

13 (12.7)

2 (2.0)

Hypokalemia

23 (22.5)

4 (3.9)

1 (1.0)

23 (22.5)

0 (0.0)

1 (1.0)

Hyperkalemia

19 (18.6)

1 (1.0)

2 (2.0)

20 (19.6)

2 (2.0)

0 (0.0)

Neurology

92 (90.2)

27 (26.5)

5 (4.9)

76 (74.5)

15 (14.7)

4 (3.9)

Neuropathy-sensory

55 (53.9)

3 (2.9)

1 (1.0)

28 (27.5)

1 (1.0)

0 (0.0)

Confusion

29 (28.4)

6 (5.9)

3 (2.9)

12 (11.8)

2 (2.0)

3 (2.9)

Anxiety / agitation

26 (25.5)

1 (1.0)

0 (0.0)

14 (13.7)

3 (2.9)

0 (0.0)

Tremor

26 (25.5)

1 (1.0)

0 (0.0)

6 (5.9)

0 (0.0)

0 (0.0)

Insomnia

23 (22.5)

0 (0.0)

0 (0.0)

48 (47.1)

5 (4.9)

0 (0.0)

Depression

22 (21.6)

2 (2.0)

0 (0.0)

24 (23.5)

1 (1.0)

0 (0.0)

Neuropathy-motor

22 (21.6)

7 (6.9)

1 (1.0)

16 (15.7)

5 (4.9)

1 (1.0)

Dizziness / lightheadedness

20 (19.6)

1 (1.0)

0 (0.0)

14 (13.7)

0 (0.0)

0 (0.0)

Constitutional Symptom s

91 (89.2)

17 (16.7)

3 (2.9)

84 (82.4)

15 (14.7)

2 (2.0)

Fatigue

81 (79.4)

14 (13.7)

3 (2.9)

72 (70.6)

12 (11.8)

2 (2.0)

Fever

24 (23.5)

1 (1.0)

0 (0.0)

20 (19.6)

3 (2.9)

0 (0.0)

Weight loss

23 (22.5)

1 (1.0)

0 (0.0)

21 (20.6)

2 (2.0)

0 (0.0)

Weight gain

22 (21.6)

1 (1.0)

0 (0.0)

13 (12.7)

0 (0.0)

0 (0.0)

Blood/Bone Marrow

88 (86.3)

25 (24.5)

9 (8.8)

96 (94.1)

10 (9.8)

10 (9.8)

Hemoglobin (decreased)

79 (77.5)

13 (12.7)

3 (2.9)

88 (86.3)

5 (4.9)

1 (1.0)

Leukocytes (decreased)

36 (35.3)

6 (5.9)

1 (1.0)­

30 (29.4)

1 (1.0)

2 (2.0)

Neutrophils (decreased)

32 (31.4)

8 (7.8)

5 (4.9)

24 (23.5)

3 (2.9)

8 (7.8)

Platelets (decreased)

24 (23.5)

2 (2.0)

2 (2.0)

34 (33.3)

3 (2.9)

0 (0.0)

Gastrointestinal

83 (81.4)

19 (18.6)

3 (2.9)

70 (68.6)

8 (7.8)

0 (0.0)

Constipation

56 (54.9)

8 (7.8)

0 (0.0)

29 (28.4)

1 (1.0)

0 (0.0)

Anorexia

29 (28.4)

4 (3.9)

0 (0.0)

25 (24.5)

2 (2.0)

0 (0.0)

Nausea

29 (28.4)

5 (4.9)

0 (0.0)

23 (22.5)

1 (1.0)

0 (0.0)

Vomiting

12 (11.8)

2 (2.0)

0 (0.0)

12 (11.8)

1 (1.0)

0 (0.0)

Diarrhea

12 (11.8)

1 (1.0)

0 (0.0)

17 (16.7)

3 (2.9)

0 (0.0)

Dyspepsia

8 (7.8)

1 (1.0)

0 (0.0)

19 (18.6)

1 (1.0)

0 (0.0)

Cardiovascular

70 (68.6)

24 (23.5)

14 (13.7)

60 (58.8)

17 (16.7)

5 (4.9)

Edema

58 (56.9)

6 (5.9)

0 (0.0)

47 (46.1)

4 (3.9)

0 (0.0)

Thrombosis/embolism

23 (22.5)

13 (12.7)

9 (8.8)

5 (4.9)

3 (2.9)

2 (2.0)

Hypotension

16 (15.7)

7 (6.9)

2 (2.0)

15 (14.7)

2 (2.0)

3 (2.9)

Hypertension

11 (10.8)

1 (1.0)

0 (0.0)

12 (11.8)

9 (8.8)

0 (0.0)

Pain

64 (62.7)

8 (7.8)

2 (2.0)

66 (64.7)

15 (14.7)

0 (0.0)

Bone pain

31 (30.4)

3 (2.9)

2 (2.0)

37 (36.3)

11 (10.8)

0 (0.0)

Pain-other

25 (24.5)

4 (3.9)

0 (0.0)

26 (25.5)

3 (2.9)

0 (0.0)

Headache

20 (19.6)

3 (2.9)

0 (0.0)

23 (22.5)

0 (0.0)

0 (0.0)

Myalgia

17 (16.7)

0 (0.0)

0 (0.0)

14 (13.7)

1 (1.0)

0 (0.0)

Arthralgia

13 (12.7)

0 (0.0)

0 (0.0)

10 (9.8)

2 (2.0)

0 (0.0)

Pulmonary

52 (51.0)

15 (14.7)

6 (5.9)

51 (50.0)

15 (14.7)

5 (4.9)

Dyspnea

43 (42.2)

10 (9.8)

3 (2.9)

32 (31.4)

12 (11.8)

4 (3.9)

Cough

15 (14.7)

0 (0.0)

0 (0.0)

19 (18.6)

0 (0.0)

0 (0.0)

Dermatology/Skin

48 (47.1)

5 (4.9)

1 (1.0)

35 (34.3)

2 (2.0)

0 (0.0)

Rash/desquamation

31 (30.4)

4 (3.9)

0 (0.0)

18 (17.6)

2 (2.0)

0 (0.0)

Dry skin

21 (20.6)

0 (0.0)

0 (0.0)

11 (10.8)

0 (0.0)

0 (0.0)

Hepatic

47 (46.1)

5 (4.9)

2 (2.0)

45 (44.1)

3 (2.9)

1 (1.0)

Alkaline phosphatase (increased)

27 (26.5)

0 (0.0)

0 (0.0)

29 (28.4)

1 (1.0)

0 (0.0)

SGOT (increased)

25 (24.5)

1 (1.0)

1 (1.0)

24 (23.5)

1 (1.0)

1 (1.0)

Bilirubin (increased)

14 (13.7)

1 (1.0)

1 (1.0)

10 (9.8)

1 (1.0)

1 (1.0)

Renal/Genitourinary

43 (42.2)

3 (2.9)

3 (2.9)

49 (48.0)

4 (3.9)

3 (2.9)

Creatinine

36 (35.3)

1 (1.0)

1 (1.0)

43 (42.2)

2 (2.0)

2 (2.0)

Musculoskeletal

42 (41.2)

8 (7.8)

2 (2.0)

41 (40.2)

11 (10.8)

3 (2.9)

Muscle weakness

41 (40.2)

6 (5.9)

1 (1.0)

38 (37.3)

10 (9.8)

3 (2.9)

Infection/Febrile Neutropenia

23 (22.5)

5 (4.9)

2 (2.0)

28 (27.5)

6 (5.9)

6 (5.9)

Infection without neutropenia

19 (17.6)

4 (3.9)

1 (1.0)

18 (17.6)

4 (3.9)

2 (2.0)

Incidence in ENL Controlled Clinical Trials

Table 7 lists treatment-emergent signs and symptoms that occurred in THALOMID® (thalidomide)-treated patients in controlled clinical trials in ENL. Doses ranged from 50 to 300 mg/day. All adverse events were mild to moderate in severity, and none resulted in discontinuation. Table 7 also lists treatment-emergent adverse events that occurred in at least three of the THALOMID® (thalidomide)-treated HIV-seropositive patients who participated in an 8-week, placebo-controlled clinical trial. Events that were more frequent in the placebo-treated group are not included. (See WARNINGS, PRECAUTIONS, and Drug Interactions)

  Table 7: Summary of Adverse Events (AEs) Reported in Celgene-sponsored Controlled Clinical Trials

All AEs Reported

AEs Reported in ≥3 HIV-seropositive Patients

Body System/Adverse Event

in ENL Patients

Thalidomide

Placebo


50 to 300 mg/day

(N=24)

100 mg/day

(N=36)

200 mg/day

(N=32)


(N=35)

Body as a Whole

16 (66.7%)

18 (50.0%)

19 (59.4%)

13 (37.1%)

Abdominal pain

1 (4.2%)

1 (2.8%)

1 (3.1%)

4 (11.4%)

Accidental injury

1 (4.2%)

2 (5.6%)

0

1 (2.9%)

Asthenia

2 (8.3%)

2 (5.6%)

7 (21.9%)

1 (2.9%)

Back pain

1 (4.2%)

2 (5.6%)

0

0

Chills

1 (4.2%)

0

3 (9.4%)

4 (11.4%)

Facial edema

1 (4.2%)

0

0

0

Fever

0

7 (19.4%)

7 (21.9%)

6 (17.1%)

Headache

3 (12.5%)

6 (16.7%)

6 (18.7%)

4 (11.4%)

Infection

0

3 (8.3%)

2 (6.3%)

1 (2.9%)

Malaise

2 (8.3%)

0

0

0

Neck pain

1 (4.2%)

0

0

0

Neck rigidity

1 (4.2%)

0

0

0

Pain

2 (8.3%)

0

1 (3.1%)

2 (5.7%)

Digestive System

5 (20.8%)

16 (44.4%)

16 (50.0%)

15 (42.9%)

Anorexia

0

1 (2.8%)

3 (9.4%)

2 (5.7%)

Constipation

1 (4.2%)

1 (2.8%)

3 (9.4%)

0

Diarrhea

1 (4.2%)

4 (11.1%)

6 (18.7%)

6 (17.1%)

Dry mouth

0

3 (8.3%)

3 (9.4%)

2 (5.7%)

Flatulence

0

3 (8.3%)

0

2 (5.7%)

Liver function tests

multiple abnormalities


0


0


3 (9.4%)


0

Nausea

1 (4.2%)

0

4 (12.5%)

1 (2.9%)

Oral moniliasis

1 (4.2%)

4 (11.1%)

2 (6.3%)

0

Tooth pain

1 (4.2%)

0

0

0

Hemic and Lymphatic

0

8 (22.2%)

13 (40.6%)

10 (28.6%)

Anemia

0

2 (5.6%)

4 (12.5%)

3 (8.6%)

Leukopenia

0

6 (16.7%)

8 (25.0%)

3 (8.6%)

Lymphadenopathy

0

2 (5.6%)

4 (12.5%)

3 (8.6%)

Metabolic and Endocrine Disorders

1 (4.2%)

8 (22.2%)

12 (37.5%)

8 (22.9%)

Edema peripheral

1 (4.2%)

3 (8.3%)

1 (3.1%)

0

Hyperlipemia

0

2 (5.6%)

3 (9.4%)

1 (2.9%)

SGOT increased

0

1 (2.8%)

4 (12.5%)

2 (5.7%)

Nervous System

13 (54.2%)

19 (52.8%)

18 (56.3%)

12 (34.3%)

Agitation

0

0

3 (9.4%)

0

Dizziness

1 (4.2%)

7 (19.4%)

6 (18.7%)

0

Insomnia

0

0

3 (9.4%)

2 (5.7%)

Nervousness

0

1 (2.8%)

3 (9.4%)

0

Neuropathy

0

3 (8.3%)

0

0

Paresthesia

0

2 (5.6%)

5 (15.6%)

4 (11.4%)

Somnolence

9 (37.5%)

13 (36.1%)

12 (37.5%)

4 (11.4%)

Tremor

1 (4.2%)

0

0

0

Vertigo

2 (8.3%)

0

0

0

Respiratory System

3 (12.5%)

9 (25.0%)

6 (18.7%)

9 (25.7%)

Pharyngitis

1 (4.2%)

3 (8.3%)

2 (6.3%)

2 (5.7%)

Rhinitis

1 (4.2%)

0

0

4 (11.4%)

Sinusitis

1 (4.2%)

3 (8.3%)

1 (3.1%)

2 (5.7%)

Skin and Appendages

10 (41.7%)

17 (47.2%)

18 (56.3%)

19 (54.3%)

Acne

0

4 (11.1%)

1 (3.1%)

0

Dermatitis fungal

1 (4.2%)

2 (5.6%)

3 (9.4%)

0

Nail disorder

1 (4.2%)

0

1 (3.1%)

0

Pruritus

2 (8.3%)

1 (2.8%)

2 (6.3%)

2 (5.7%)

Rash

5 (20.8%)

9 (25.0%)

8 (25.0%)

11 (31.4%)

Rash maculo‑papular

1 (4.2%)

6 (16.7%)

6 (18.7%)

2 (5.7%)

Sweating

0

0

4 (12.5%)

4 (11.4%)

Urogenital System

2 (8.3%)

6 (16.7%)

2 (6.3%)

4 (11.4%)

Albuminuria

0

3 (8.3%)

1 (3.1%)

2 (5.7%)

Hematuria

0

4 (11.1%)

0

1 (2.9%)

Impotence

2 (8.3%)

1 (2.8%)

0

0

Other Adverse Events Observed in ENL Patients

Thalidomide in doses up to 400 mg/day has been administered investigationally in the United States over a 19-year period in 1465 patients with ENL. The published literature describes the treatment of an additional 1678 patients. To provide a meaningful estimate of the proportion of the individuals having adverse events, similar types of events were grouped into a smaller number of standardized categories using a modified COSTART dictionary/terminology. These categories are used in the listing below. All reported events are included except those already listed in the previous table. Due to the fact that these data were collected from uncontrolled studies, the incidence rate cannot be determined. As mentioned previously, no causal relationship between thalidomide and these events can be conclusively determined at this time. These are reports of all adverse events noted by investigators in patients to whom they had administered thalidomide.

Body as a Whole: Abdomen enlarged, fever, photosensitivity, upper extremity pain.

Cardiovascular System: Bradycardia, hypertension, hypotension, peripheral vascular disorder, tachycardia, vasodilation.

Digestive System: Anorexia, appetite increase/weight gain, dry mouth, dyspepsia, enlarged liver, eructation, flatulence, increased liver function tests, intestinal obstruction, vomiting.

Hemic and Lymphatic: ESR decrease, eosinophilia, granulocytopenia, hypochromic anemia, leukemia, leukocytosis, leukopenia, MCV elevated, RBC abnormal, spleen palpable, thrombocytopenia.

Metabolic and Endocrine: ADH inappropriate, amyloidosis, bilirubinemia, BUN increased, creatinine increased, cyanosis, diabetes, edema, electrolyte abnormalities, hyperglycemia, hyperkalemia, hyperuricemia, hypocalcemia, hypoproteinemia, LDH increased, phosphorus decreased, SGPT increased.

Muscular Skeletal: Arthritis, bone tenderness, hypertonia, joint disorder, leg cramps, myalgia, myasthenia, periosteal disorder.

Nervous System: Abnormal thinking, agitation, amnesia, anxiety, causalgia, circumoral paresthesia, confusion, depression, euphoria, hyperesthesia, insomnia, nervousness, neuralgia, neuritis, neuropathy, paresthesia, peripheral neuritis, psychosis.

Respiratory System: Cough, emphysema, epistaxis, pulmonary embolus, rales, upper respiratory infection, voice alteration.

Skin and Appendages: Acne, alopecia, dry skin, eczematous rash, exfoliative dermatitis, ichthyosis, perifollicular thickening, skin necrosis, seborrhea, sweating, urticaria, vesiculobullous rash.

Special Senses: Amblyopia, deafness, dry eye, eye pain, tinnitus.

Urogenital: Decreased creatinine clearance, hematuria, orchitis, proteinuria, pyuria, urinary frequency.

Other Adverse Events Observed in HIV-seropositive Patients

In addition to controlled clinical trials, THALOMID® (thalidomide) has been used in uncontrolled studies in 145 patients. Less frequent adverse events that have been reported in these HIV-seropositive patients treated with THALOMID® (thalidomide) were grouped into a smaller number of standardized categories using modified COSTART dictionary/terminology and these categories are used in the listing below. Adverse events that have already been included in the tables and narrative above, or that are too general to be informative are not listed.

Body as a Whole: Ascites, AIDS, allergic reaction, cellulitis, chest pain, chills and fever, cyst, decreased CD4 count, facial edema, flu syndrome, hernia, thyroid hormone level altered, moniliasis, photosensitivity reaction, sarcoma, sepsis, viral infection.

Cardiovascular System: Angina pectoris, arrhythmia, atrial fibrillation, bradycardia, cerebral ischemia, cerebrovascular accident, congestive heart failure, deep thrombophlebitis, heart arrest, heart failure, hypertension, hypotension, murmur, myocardial infarct, palpitation, pericarditis, peripheral vascular disorder, postural hypotension, syncope, tachycardia, thrombophlebitis, thrombosis.

Digestive System: Cholangitis, cholestatic jaundice, colitis, dyspepsia, dysphagia, esophagitis, gastroenteritis, gastrointestinal disorder, gastrointestinal hemorrhage, gum disorder, hepatitis, pancreatitis, parotid gland enlargement, periodontitis, stomatitis, tongue discoloration, tooth disorder.

Hemic and Lymphatic: Aplastic anemia, macrocytic anemia, megaloblastic anemia, microcytic anemia.

Metabolic and Endocrine: Avitaminosis, bilirubinemia, dehydration, hypercholesteremia, hypoglycemia, increased alkaline phosphatase, increased lipase, increased serum creatinine, peripheral edema.

Muscular Skeletal: Myalgia, myasthenia.

Nervous System: Abnormal gait, ataxia, decreased libido, decreased reflexes, dementia, dysesthesia, dyskinesia, emotional lability, hostility, hypalgesia, hyperkinesia, incoordination, meningitis, neurologic disorder, tremor, vertigo.

Respiratory System: Apnea, bronchitis, lung disorder, lung edema, pneumonia (including Pneumocystis carinii pneumonia), rhinitis.

Skin and Appendages: Angioedema, benign skin neoplasm, eczema, herpes simplex, incomplete Stevens-Johnson syndrome, nail disorder, pruritus, psoriasis, skin discoloration, skin disorder.

Special Senses: Conjunctivitis, eye disorder, lacrimation disorder, retinitis, taste perversion.

Other Adverse Events Observed in Post-Marketing Use

Cardiovascular System: Cardiac arrhythmias including atrial fibrillation, bradycardia, tachycardia, sick sinus syndrome and EKG abnormalities.

Digestive System: Intestinal perforation.

Metabolic and Endocrine: Electrolyte imbalance including hypercalcemia or hypocalcemia, hyperkalemia and hypokalemia, hyponatremia, hypothyroidism, and increased alkaline phosphatase, tumor lysis syndrome.

Nervous System: Changes in mental status or mood including depression and suicide attempts, disturbances in consciousness including lethargy, syncope, loss of consciousness or stupor, seizures including grand mal convulsions and status epilepicus.

Skin and Appendages: Erythema multiforme.

Hemic and Lymphatic: Decreased white blood cell counts including neutropenia and febrile neutropenia, changes in prothrombin time.

Respiratory System: Pleural effusion .

Other Adverse Events in the Published Literature or Reported from Other Sources

The following additional events have been identified either in the published literature or from spontaneous reports from other sources: acute renal failure, amenorrhea, aphthous stomatitis, bile duct obstruction, carpal tunnel, chronic myelogenous leukemia, diplopia, dysesthesia, dyspnea, enuresis, erythema nodosum, erythroleukemia, foot drop, galactorrhea, gynecomastia, hangover effect, hypomagnesemia, hypothyroidism, lymphedema, lymphopenia, metrorrhagia, migraine, myxedema, nodular sclerosing Hodgkin’s disease, nystagmus, oliguria, pancytopenia, petechiae, purpura, Raynaud’s syndrome, stomach ulcer, and suicide attempt.



REPORTS OF SUSPECTED THALOMID SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Thalomid. The information is not vetted and should not be considered as verified clinical evidence.

Possible Thalomid side effects / adverse reactions in 52 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-05

Patient: 52 year old male weighing 67.0 kg (147.4 pounds)

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Suspect drug(s):
Cisplatin
    Indication: Multiple Myeloma
    Start date: 2005-06-29

Cyclophosphamide
    Indication: Multiple Myeloma
    Start date: 2005-06-29

Dexamethasone
    Indication: Multiple Myeloma
    Start date: 2005-06-29
    End date: 2008-07-03

Doxorubicin HCL
    Indication: Multiple Myeloma
    Start date: 2005-06-29

Etoposide
    Indication: Multiple Myeloma
    Start date: 2005-06-29

Melphalan Hydrochloride
    Start date: 2009-10-15

Melphalan Hydrochloride
    Indication: Multiple Myeloma

Thalomid
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2005-06-29
    End date: 2008-07-03

Velcade
    Indication: Multiple Myeloma
    Start date: 2005-06-29



Possible Thalomid side effects / adverse reactions in 81 year old female

Reported by a pharmacist from Australia on 2011-10-14

Patient: 81 year old female

Reactions: Product Packaging Issue, Dyspnoea, Joint Swelling, Insomnia, Cardiac Disorder

Suspect drug(s):
Thalomid



Possible Thalomid side effects / adverse reactions in 52 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-18

Patient: 52 year old male weighing 67.0 kg (147.4 pounds)

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Suspect drug(s):
Cisplatin
    Indication: Multiple Myeloma
    Start date: 2005-06-29

Cyclophosphamide
    Indication: Multiple Myeloma
    Start date: 2005-06-29

Dexamethasone
    Indication: Multiple Myeloma
    Start date: 2005-06-29
    End date: 2008-07-03

Doxorubicin HCL
    Indication: Multiple Myeloma
    Start date: 2005-06-29

Etoposide
    Indication: Multiple Myeloma
    Start date: 2005-06-29

Melphalan Hydrochloride
    Start date: 2009-10-15

Melphalan Hydrochloride
    Indication: Multiple Myeloma

Thalomid
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2005-06-29
    End date: 2008-07-03

Velcade
    Indication: Multiple Myeloma
    Start date: 2005-06-29



See index of all Thalomid side effect reports >>

Drug label data at the top of this Page last updated: 2007-04-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012